Skip to main content

Table 1 Current dosimetric guidelines and isodose volumes stratified by ENI

From: Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy

 

Goal1

No ENI

ENI

p2

Rectum

 

Mean (±SD)

 

V70

<10 cc3

2.1 cc (±1.5 cc)

2.4 cc (± 2.0 cc)

0.369

V60

<10 cc4

8.3 cc (±4.2 cc)

9.2 cc (±5.0 cc)

0.158

V50

<17%4

19.5% (±9.1%)

23.0% (±10.6%)

0.021

V30

<35%4

53.6% (±20.0%)

69.8% (±21.4%)

<0.001

Bladder

    

V60

<10%4

12.1% (±10.1%)

13.4% (±10.8%)

0.197

V50

<25%4

20.5% (±15.2%)

27.1% (±15.7%)

<0.001

V30

<50%4

47.2% (±28.0%)

72.9% (±25.5%)

<0.001

  1. 1Current guidlines; treatment planning goals have become more strict since initially implemented. 2Independent samples Kruskal-Wallis test. 3Prioritized greater than PTV coverage. 4Planning goal but less important than PTV coverage. Bolded text indicates a statistically significant difference.